Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)13.56
  • Today's Change0.69 / 5.36%
  • Shares traded73.96k
  • 1 Year change+29.14%
  • Beta1.5847
Data delayed at least 15 minutes, as of Nov 22 2024 18:07 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

AVITA Medical, Inc. is a commercial-stage regenerative medicine company. The Company is a provider of regenerative medicine addressing unmet medical needs in burn injuries, full-thickness skin defects, and in skin repigmentation, such as vitiligo. Its RECELL platform a single use, stand-alone, battery operated, autologous cell harvesting device containing enzymatic and buffer solutions, sterile surgical instruments, and actuators. RECELL is used for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. The platform technology of the RECELL System enables a thin split-thickness skin sample from the patient to be processed and prepared, producing an autologous cellular suspension called Spray-On Skin Cells. These Spray-On Skin Cells are prepared at the point of care in as little as 30 minutes, providing a new way to treat thermal burn wounds and full-thickness skin defects.

  • Revenue in USD (TTM)60.04m
  • Net income in USD-57.32m
  • Incorporated2020
  • Employees207.00
  • Location
    AVITA Medical Inc28159 Avenue Stanford, Suite 220VALENCIA 91355United StatesUSA
  • Phone+1 (661) 367-9170
  • Websitehttps://www.avitamedical.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Aclaris Therapeutics Inc27.08m-37.00m308.58m91.00--2.37--11.40-0.5198-0.51980.38061.820.1352--78.61297,582.40-18.47-47.29-20.87-53.8753.5344.00-136.65-549.18----0.00--5.0338.41-1.81---0.703--
Kodiak Sciences Inc0.00-191.62m310.43m108.00--1.67-----3.65-3.650.003.520.00----0.00-41.64-31.73-46.43-33.61------------0.00------21.97--134.76--
Design Therapeutics Inc0.00-47.78m315.38m54.00--1.25-----0.8465-0.84650.004.460.00----0.00-17.02---17.64--------------0.00-------5.61------
AC Immune SA46.22m-44.97m325.51m133.00--2.22--7.04-0.4608-0.46080.47831.480.2116--3.19347,510.10-20.59-18.25-29.04-19.52-----97.29-148.29---14.570.0231--276.1415.5223.35---15.49--
Jasper Therapeutics Inc0.00-63.53m327.63m45.00--3.92-----4.75-4.750.005.580.00----0.00-60.56---68.51--------------0.00-------71.06------
Q32 Bio Inc0.00-49.66m329.37m42.00--17.94-----7.44-7.440.001.510.00----0.00-27.86-34.98-33.25-37.92-------971.76----0.4079---63.97-26.32-2,156.96---60.90--
AVITA Medical Inc60.04m-57.32m337.42m207.00--27.60--5.62-2.23-2.232.330.46640.74091.537.30290,048.30-70.74---86.14--86.46---95.47--3.37-11.270.7768--45.68---32.69------
enGene Holdings Inc0.00-123.44m339.13m33.00--1.47-----4.77-4.770.005.210.00----0.00-78.13---84.20-------------3.140.0906-------260.87------
Codexis Inc64.45m-62.09m352.37m174.00--4.80--5.47-0.878-0.8780.91490.9020.42597.033.62370,379.30-41.03-17.13-54.21-20.2375.9677.29-96.35-37.043.15--0.2806---49.392.97-126.96--9.80--
XOMA Royalty Corp21.61m-35.43m354.31m13.00--4.17--16.40-3.06-3.061.867.210.1244--39.721,662,000.00-17.25-4.55-18.97-4.94-----138.67-31.87----0.5817---21.06-2.13-105.10--23.16--
Prime Medicine Inc800.00k-219.25m356.49m234.00--2.06--445.61-2.05-2.050.00731.440.0028----3,418.80-76.67---88.64-------27,406.13------0.00-------39.52------
Silence Therapeutics plc22.53m-50.47m358.35m115.00--5.45--15.91-0.4057-0.40570.181.010.1273--2.56195,915.70-28.51-43.60-32.89-54.9156.40---224.01-287.30----0.0016--44.99---6.86--156.10--
Northwest Biotherapeutics Inc1.60m-75.96m367.18m25.00------230.06-0.0631-0.06310.0013-0.04990.0525----63,840.00-244.93-381.58---------4,666.29-6,479.25---27.91----14.8036.2138.71--77.88--
Alector Inc61.51m-158.41m368.23m241.00--3.10--5.99-1.71-1.710.66071.210.1035----252,082.00-26.66-20.00-35.58-23.81-----257.54-124.07----0.00---27.3628.522.19--4.79--
Contineum Therapeutics Inc0.00-35.46m369.65m31.00--1.76-----1.39-1.390.008.170.00----0.00-19.97---20.75--------------0.00------193.68------
Data as of Nov 22 2024. Currency figures normalised to AVITA Medical Inc's reporting currency: US Dollar USD

Institutional shareholders

19.25%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 30 Sep 20241.72m6.62%
The Vanguard Group, Inc.as of 30 Sep 20241.37m5.26%
Geode Capital Management LLCas of 30 Sep 2024594.44k2.29%
SSgA Funds Management, Inc.as of 30 Sep 2024520.00k2.00%
Essex Investment Management Co. LLCas of 30 Sep 2024231.09k0.89%
Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2024212.93k0.82%
AWM Investment Co., Inc.as of 30 Sep 202498.17k0.38%
Morgan Stanley & Co. LLCas of 30 Sep 202489.48k0.34%
Jane Street Capital LLCas of 30 Sep 202489.40k0.34%
Legato Capital Management LLCas of 30 Sep 202479.37k0.31%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.